(Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating ...
News Medical on MSN
Stem cell implants aim to restore dopamine in Parkinson’s disease
Parkinson's disease is a progressive neurodegenerative disorder that affects more than one million people in the United States, with approximately 90,000 new cases diagnosed each year. Although ...
Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced new clinical data presented at the 2026 Tandem ...
Fortress Biotech, Inc. and its subsidiary Helocyte, Inc. have initiated a Phase 2 clinical trial to assess the efficacy of the Triplex vaccine, designed to prevent cytomegalovirus (CMV) reactivation ...
Scientists at Keck Medicine of USC are testing an experimental stem cell therapy that aims to restore the brain’s ability to ...
A first-in-human pilot trial suggests umbilical cord–derived mesenchymal stem cell eye drops may safely improve symptoms and ...
Eyestem Research Pvt Ltd, a biotechnology company developing advanced scalable cell therapy solutions for blindness caused by ...
Orca Bio announced new clinical data presented at the 2026 Tandem Meetings of ASTCT® and CIBMTR® from February 4-7 in Salt Lake City.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results